Case Study: Running an Adaptive Early-Phase RAS Oncology Trial

Rapid activation established momentum. Continuous operational readiness sustained execution as study strategy evolved.

In early-phase oncology, regulatory milestones, enrollment trends, safety review requirements, and evolving development strategies can all reshape study operations while the trial remains active.

For this first-in-human Phase I study evaluating a RAS-PI3Kα inhibitor in patients with advanced solid tumors harboring KRAS, HRAS, or NRAS mutations, Precision supported rapid start-up activities, coordinated dose-escalation and dose-expansion planning, managed repeated safety review deliverables, and maintained readiness across multiple regions as sponsor priorities evolved. Study execution required teams to balance immediate operational demands while remaining prepared for future expansion opportunities.

The result was a study that maintained momentum despite shifting strategic requirements. Sites activated rapidly, enrollment remained strong, and cross-functional teams delivered repeated data reviews while preserving flexibility for future country expansion.

Study Overview

The study began with an aggressive start-up strategy focused on activating experienced early-phase sites capable of moving quickly through regulatory processes. Three U.S. sites completed ethics approval and activation during the same period, creating a foundation for accelerated enrollment activities.

Following site activation on February 21, 2025, the study enrolled its first participant on March 5 and recorded first treatment on March 10. The interval between first site initiation and first participant enrollment was twelve days. The interval between enrollment and first treatment was five days. These milestones established operational momentum at the beginning of the study.

As enrollment accelerated, the sponsor advanced expansion planning earlier than anticipated. Escalation and expansion activities began running in parallel, creating overlapping regulatory, operational, and resource demands.

Strategic Focus for Early-Phase Precision Oncology

The study’s early momentum depended on decisions made across several connected functions. Site selection and advance preparation supported rapid activation, while close coordination among Project Management, Clinical Operations, Regulatory, and Data Management allowed the team to absorb new requirements as the development strategy evolved.

Three areas became particularly important: activating experienced early-phase sites, managing escalation and expansion activities in parallel, and maintaining continuous data readiness for safety review. Together, these capabilities helped the team sustain progress while preserving flexibility across active and planned regions.

Supporting Rapid Activation Through Site Readiness

The initial operational strategy centered on selecting high-performing early-phase oncology sites and ensuring submissions, approvals, and activation activities were coordinated as efficiently as possible.

Three initial U.S. sites completed EC/IRB approval and activation within seventeen days of submission. This coordinated approach enabled rapid progression from regulatory activities into active enrollment operations while preserving quality and compliance oversight. The strategy also leveraged established sponsor and site relationships, allowing teams to move quickly once approvals were finalized.

Managing Simultaneous Escalation and Expansion

Shortly after activation, sponsor priorities shifted. While escalation cohorts remained active, planning began for future expansion activities.

The eventual decision to pause expansion countries created a second layer of complexity. Teams were required to preserve documentation, site readiness, regulatory status, and operational knowledge while adapting budgets and future planning assumptions. The ability to maintain readiness while responding to changing sponsor priorities became a defining feature of study execution.

Maintaining Continuous Data Readiness

Perhaps the most operationally demanding aspect of the study involved repeated Safety Review Committee reviews and associated data cuts. Study teams frequently received only limited notice before SRC meetings. Clinical Operations, Data Management, and sponsor teams worked continuously to maintain data currency, reconcile records, resolve queries, and support ongoing safety evaluation.

According to study leadership, this level of activity required dedicated Data Management focus and substantial cross-functional coordination. Teams remained prepared for repeated reviews while continuing normal study operations. The result was sustained data readiness despite compressed review timelines and evolving study requirements.

From Rapid Activation to Continuous Readiness

Preserving Momentum Across an Evolving Study

The operational value of this approach became most visible when the study moved beyond its original execution path. Enrollment performance changed the need for additional activated countries, dose-expansion planning accelerated, and frequent SRC reviews increased the demand for current, review-ready data.

Because the underlying workstreams remained connected, each change could be managed within the broader development strategy. Completed regulatory work retained value. Site relationships remained available for future use. Clinical Operations and Data Management could respond to safety review requirements without rebuilding readiness for each data cut.

This continuity allowed the sponsor to evaluate new cohorts, regional plans, and expansion options while the active study continued to progress. The team preserved completed work, maintained visibility across outstanding decisions, and kept future paths executable as priorities changed.

The study ultimately demonstrated the value of an operating model that can absorb change without repeatedly resetting execution. That capability carried the program from rapid activation into sustained operational readiness.

Running Adaptive Early-Phase Oncology Programs

This study required the team to support active enrollment, dose-finding decisions, expansion planning, regulatory preparation, and repeated safety reviews within the same evolving program. Maintaining continuity across those demands allowed execution to progress while the sponsor assessed multiple development paths.

The experience also showed how decisions in one area can reshape requirements elsewhere. Enrollment performance influenced regional plans. SRC timing affected Clinical Operations and Data Management resourcing. Country pauses created an ongoing need for regulatory tracking, site communication, and restart readiness.

Early-phase oncology sponsors need operating teams that can maintain control as these dependencies emerge. Integrated planning across site start-up, regulatory, clinical, data, and project functions helps preserve momentum while development priorities continue to evolve.

Precision combines early-phase operational expertise, integrated data management, regulatory coordination, and site activation capabilities to support adaptive development strategies from first patient through expansion planning.